Complications of myeloma and its treatments

Hemostatic Abnormalities in Multiple Myeloma Patients. Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130. Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print]. Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem…

Journal, Library, Management of complications & side effects

Results from TEAMM clinical trial reported

Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…

News

Carfilzomib treatment associated with cardiovascular events in myeloma patients

A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…

News

Supportive treatments

Mobilization of Hematopoietic Progenitor Cells with Standard or Reduced Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients. a Randomized Prospective Single Center Phase II Study. Samaras P et al. Biol Blood Marrow Transplant. 2017 Dec 12. pii: S1083-8791(17)31679-8. doi: 10.1016/j.bbmt.2017.12.775. [Epub ahead of print]. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.…

Journal, Library, Myeloma Prognosis & Outcomes

General

Falls in Older Adults with Multiple Myeloma. Wildes TM et al. Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13009. [Epub ahead of print]. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations From the Organizing Committee. Holstein SA et al. Biol Blood Marrow Transplant. 2017 Dec 11. pii: S1083-8791(17)31678-6. doi: 10.1016/j.bbmt.2017.12.774. [Epub ahead of print]. Multiple Myeloma and Bone:…

Journal, Library

Current treatments

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV et al. N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678. [Epub ahead of print]. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Auner HW et al. Haematologica. 2017…

Journal, Library

Complications of myeloma and its treatments

Gastric submucosal haematoma caused by an amyloidoma in the setting of multiple myeloma. Pak SC et al. Arab J Gastroenterol. 2017 Dec 14. pii: S1687-1979(17)30116-8. doi: 10.1016/j.ajg.2017.12.002. [Epub ahead of print]. A case of Multiple Myeloma presenting with diffuse osteosclerosis and multiple bone infarcts. Vignon M et al. Joint Bone Spine. 2017 Dec 9. pii: S1297-319X(17)30203-8. doi: 10.1016/j.jbspin.2017.11.013. [Epub ahead of print]. Systolic dysfunction associated…

Journal, Library, Management of complications & side effects